Brief: Briacell’S Bria-Imt™ Demonstrates Survival Advantage Over Trodelvy® And Control Group In Metastatic Breast Cancer
11/07/2025 12:33
July 11 (Reuters) - Briacell Therapeutics Corp BCT.TO: BRIACELL’S BRIA-IMT™ DEMONSTRATES SURVIVAL ADVANTAGE OVER TRODELVY® AND CONTROL GROUP IN METASTATIC BREAST CANCER BRIACELL THERAPEUTICS CORP - NO TREATMENT-RELATED DISCONTINUATIONS REPORTED FOR BRIACELL'S BRIA-IMT BRIACELL THERAPEUTICS CORP - ANNOUNCES UPDATED PHASE 2 DATA FOR BRIA-IMT BRIACELL THERAPEUTICS CORP - BRIA-IMT SHOWS 13.9 MONTHS OS IN TNBC BRIACELL THERAPEUTICS CORP - BRIA-IMT SHOWS 17.3 MONTHS OS IN HR+ BREAST CANCER Source text: ID:nGNX4q7xFD Further company coverage: BCT.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study